|
| | Oridonin Basic information |
| Product Name: | Oridonin | | Synonyms: | ISODONAL;(14r)-7-alpha,20-epoxy-1-alpha,6-beta,7,14-tetrahydroxykaur-16-en-15-one;(1-alpha,6-beta,7-alpha,14r)-7,20-epoxy-1,6,7,14-tetrahydroxykaur-16-en-15-o;,14r)-;20-epoxy-1-alpha,6-beta,7,14-tetrahydroxy-7-alph(14r)-kaur-16-en-15-on;kaur-16-en-15-one,7,20-epoxy-1,6,7,14-tetrahydroxy-,(1-alpha,6-beta,7-alpha;Rubescensin;Rabdosia rubescens | | CAS: | 28957-04-2 | | MF: | C20H28O6 | | MW: | 364.44 | | EINECS: | | | Product Categories: | Inhibitors;chemical reagent;pharmaceutical intermediate;phytochemical;reference standards from Chinese medicinal herbs (TCM).;standardized herbal extract;Miscellaneous Natural Products;Natural Plant Extract | | Mol File: | 28957-04-2.mol |  |
| | Oridonin Chemical Properties |
| Melting point | 248-250°C | | Boiling point | 599.8±50.0 °C(Predicted) | | density | 1.42±0.1 g/cm3(Predicted) | | storage temp. | Sealed in dry,Room Temperature | | solubility | DMSO: >20mg/mL | | pka | 10.96±0.70(Predicted) | | form | Yellow solid | | color | White or off-white | | Stability: | Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 2 months. |
| Hazard Codes | Xn | | Risk Statements | 40 | | Safety Statements | 36/37-24/25 | | WGK Germany | 2 | | RTECS | NZ8177000 | | HS Code | 29389090 |
| | Oridonin Usage And Synthesis |
| Description | Oridonin is a diterpenoid that has been found in R. rubescens and has anti-inflammatory and anticancer properties. It is an inhibitor of AKT1 and AKT2 (IC50s = 8.4 and 8.9 μM, respectively). Oridonin inhibits proliferation of KYSE70, KYSE410, and KYSE450 esophageal cancer cells in a dose-dependent manner, halts the cell cycle at the G2/M phase, and induces apoptosis when used at a concentration of 20 μM. It decreases the expression of cleaved poly(ADP-ribose) polymerase (PARP), caspase-3, caspase-7, and Bims and the protein levels of phosphorylated AKT and reduces AKT activity. Oridonin reduces tumor growth in patient-derived mouse tumor models when administered at doses of 40 and 160 mg/kg. Oridonin is also an inhibitor of NLRP3 inflammasome assembly and activation. It inhibits inflammation in wild-type, but not Nlrp3-/-, mice in a model of high-fat diet-induced type 2 diabetes when administered at a dose of 3 mg/kg. | | Uses | Oridonin is an effective anticancer agent due to its ability to inhibit proliferation and induce apoptosis of human osteosarcoma cells. Blocks Wnt/β-catenin signalling. | | Definition | ChEBI: Oridonin is an organic heteropentacyclic compound and ent-kaurane diterpenoid with formula C20H28O6 isolated from the leaves of the medicinal herb Rabdosia rubescens. It has a role as an antineoplastic agent, an angiogenesis inhibitor, an apoptosis inducer, an anti-asthmatic agent, a plant metabolite and an antibacterial agent. It is an organic heteropentacyclic compound, an enone, a cyclic hemiketal, a secondary alcohol and an ent-kaurane diterpenoid. | | Pharmacokinetics | The anti-inflammatory property of oridonin has been well documented in various immunological diseases. The compound is able to counteract the expression of COX-2 and NOS-2 in the murine RAW 264.7 macrophage cell line activated with LPS. The mechanism underlies the direct interference of the compound with the active region of NF-κB, thereby blocking its nuclear localisation and reducing inflammation (Leung et al., 2005). Shang et al. (2016) observed the efficacy of oridonin against RA-FLS proliferation. They found that oridonin inhibited cell proliferation and promoted cell apoptosis in IL-1β–treated FLS through phosphorylation of ERK1/2 and JNK in a dose-dependent manner. Oridonin is also reported to restrict the release of pro-inflammatory cytokines in LPS-activated RAW264.7 macrophages (Shang et al., 2016). | | References | 1) He?et al.?(2018),?Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity; Nat. Commun.,?9?2550
2) Huang?et al.?(2018),?Oridonin inhibits vascular inflammation by blocking NF-kB and MAPK activation; Eur. J. Pharmacol.,?826?133
3) Sun?et al.?(2018),?Oridonin inhibits aberrant AKT activation in breast cancer; Oncotarget,?9?23878
4) Li?et al.?(2018),?Oridonin inhibits migration, invasion, adhesion and TGF-?1-induced epithelial-mesenchymal transition of melanoma cells by inhibiting the activity?of PI3K/Akt/GSK-3? signaling pathway; Oncol. Lett.,?15?1362
5) Lu et al. (2018),?Oridonin exerts anticancer effect on osteosarcoma by activating PPARγ and inhibiting Nrf2 pathway; Cell Death Dis.,?9?15 |
| | Oridonin Preparation Products And Raw materials |
|
